Nurtec orally disintegrating tablet, or ODT, is the brand name for the prescription drug rimegepant and is manufactured by Biohaven Pharmaceutical Holding Company Ltd., now a part of Pfizer Inc. The U.S. Food and Drug Administration (FDA) approval for this migraine relief drug came in 2021. There are no generic versions of the drug yet.
Rimegepant belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors, medications that block CGRP from binding to CGRP receptors. Among other processes, CGRP is known to cause the dilation of cerebral and dural blood vessels, the release of inflammatory mediators, and the transmission of signals from intracranial blood vessels to the nervous system, all of which are factors associated with migraine headaches. Nurtec ODT is thought to inhibit all of these.
Nurtec ODT is meant for the acute treatment of migraine attacks, with or without aura, and as a preventative medication for episodic migraines. There are different types of migraine auras. They are sensory, motor, and/or speech-related warning signs of a migraine that include muscle weakness, vision changes, sensitivity to touch, ringing in your ears, numbness, tingling, and trouble with speaking and concentrating.
According to the company website, Nurtec ODT can provide relief from migraine pain in just two hours and keep you free from headaches for up to 48 hours. In clinical trials, some people were able to resume their normal activities in 60 minutes. The dissolvable drug can also allegedly reduce the number of migraine headaches you get in a month. Per clinical trials, people noticed 4.3 fewer monthly migraine days (MMD) during weeks 9-12 when consuming Nurtec ODT.